BACKGROUND Patients with acute myocardial infarction (AMI) complicated by acute heart failure or cardiogenic shock
DATA COLLECTION. Demographic, hemodynamic, severity of illness, and comorbidity data were collected at baseline. Routine follow-up data were collected at 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, and every 6 months thereafter.
Data on major adverse events was collected as the events occurred.
DEFINITIONS. The diagnosis of AMI was entered into the INTERMACS database on the basis of clinical and laboratory data at the implanting center. AMI was either the admitting diagnosis or a major complication during the hospitalization that resulted in VAD implantation. Adverse effects have been previously defined (4). The INTERMACS profiles 1 to 7 further characterize the severity of illness in advanced heart failure patients (5) (Online Table 1 ).
FOLLOW-UP. Follow-up for all study events was continued through March 31, 2014.
STATISTICAL ANALYSIS. Continuous variables were described with the median and interquartile range and compared using the nonparametric Mann-Whitney U test. Categorical variables were described with frequencies and compared using chi-square tests.
Adverse event rates were calculated as events per 100 patient-months of follow-up and stratified as early Values are median (interquartile range) and n (%).
VAD in Myocardial Infarction
AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass graft. Acharya et al.
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Of AMI patients who were INTERMACS profile 1 at implantation, 89.8% were alive with VAD in place, 9% had died, and 1. ADVERSE EVENTS. Compared with the non-AMI group, the AMI group had higher early rates for bleeding, arrhythmia, infection, neurological dysfunction, renal dysfunction, thromboembolism, and respiratory failure; a lower early rate for Acharya et al.
rehospitalization; and a lower late rate for right heart failure and cardiac arrhythmias ( Table 4) . Acharya et al.
A Competing outcomes curves for patients with acute myocardial infarction (AMI) undergoing left ventricular assist device placement, stratified by age (<55 years: n ¼ 187; 55 to 65: n ¼ 206; >65: n ¼ 109). Older patients had lower overall survival than did younger patients. However, 1-month survival was similar among the 3 groups and survival differences were more prominent starting 3 months after left ventricular assist device implantation. Acharya et al. The lower pre-existing cardiovascular burden and the absence of long-term effects of heart failure, such as cardiac cachexia and right heart failure, may have accounted for some of the differences in mortality.
These findings corroborate a recent study that showed that shorter duration of heart failure at LVAD implantation mitigates some of the risks of high acuity (18 (19, 20) . Acharya et al.
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